Inventor
PETERSON JOHN M
US43 patents
⚠️ This page may combine multiple inventors who share the name “PETERSON JOHN M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NEUROGEN CORP
21 patentsUS6316617B1Nov 13, 2001
Certain amido-and amino-substituted benzylamine derivatives; a new class of Neuropeptide Y1 specific ligands
NEUROGEN CORP17 citations92
US6133265AOct 17, 2000
Certain amido- and amino- substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
NEUROGEN CORP33 citations92
US6069251AMay 30, 2000
Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4- substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
NEUROGEN CORP25 citations92
US5962455AOct 5, 1999
Certain substituted benzylamine derivatives a new class of neuropeptide Y1 specific ligands
NEUROGEN CORP44 citations92
US5712392AJan 27, 1998
Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
NEUROGEN CORP21 citations92
US5633377AMay 27, 1997
4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
NEUROGEN CORP18 citations92
US7160879B2Jan 9, 2007
Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
NEUROGEN CORP26 citations90
US7253168B2Aug 7, 2007
Substituted 1-benzyl-4-substituted piperazine analogues
NEUROGEN CORP13 citations82
US5656762AAug 12, 1997
4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands
NEUROGEN CORP9 citations82
US6797824B2Sep 28, 2004
Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
NEUROGEN CORP4 citations74
US6358955B1Mar 19, 2002
Substituted imidazoles as subtype specific dopamine receptor ligands and pharmaceutical compositions containing such substituted imidazole
NEUROGEN CORP5 citations74
US5985873ANov 16, 1999
Certain substituted benzylamine derivatives a new class of Neuropeptide-Y1 specific ligands
NEUROGEN CORP9 citations74
US5646281AJul 8, 1997
Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
NEUROGEN CORP6 citations74
US6916819B2Jul 12, 2005
Benzimidazole and pyridylimidazole derivatives
NEUROGEN CORP5 citations73
US6953801B2Oct 11, 2005
Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
NEUROGEN CORP11 citations72
US6420365B1Jul 16, 2002
Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
NEUROGEN CORP9 citations72
US6358949B1Mar 19, 2002
Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
NEUROGEN CORP10 citations72
US7728009B1Jun 1, 2010
Thiazole amides, imidazole amides and related analogues
NEUROGEN CORP6 citations61
US7851474B2Dec 14, 2010
Dipiperazinyl ketones and related analogues
NEUROGEN CORP3 citations60
US7241765B2Jul 10, 2007
Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
NEUROGEN CORP0 citations50
US7081458B2Jul 25, 2006
Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
NEUROGEN CORP1 citations50
GLYCOMIMETICS INC
8 patentsUS11072625B2Jul 27, 2021
Highly potent multimeric e-selectin antagonists
GLYCOMIMETICS INC4 citations73
US10519181B2Dec 31, 2019
Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
GLYCOMIMETICS INC4 citations73
US11197877B2Dec 14, 2021
Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
GLYCOMIMETICS INC2 citations70
US11780873B2Oct 10, 2023
Highly potent multimeric e-selectin antagonists
GLYCOMIMETICS INC1 citations62
US11878026B2Jan 23, 2024
Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
GLYCOMIMETICS INC0 citations59
US11845771B2Dec 19, 2023
Heterobifunctional inhibitors of E-selectin and galectin-3
GLYCOMIMETICS INC1 citations57
US11548908B2Jan 10, 2023
Heterobifunctional inhibitors of E-selectin and galectin-3
GLYCOMIMETICS INC0 citations50
US11873317B2Jan 16, 2024
Galectin-3 inhibiting c-glycosides
GLYCOMIMETICS INC0 citations47
JUNIPER NETWORKS INC
5 patentsUS11456955B2Sep 27, 2022
Tenant-based mapping for virtual routing and forwarding
JUNIPER NETWORKS INC2 citations73
US12556471B2Feb 17, 2026
Route cost based on route metrics and path type preference
JUNIPER NETWORKS INC0 citations62
US12155553B2Nov 26, 2024
Metric-based multi-hop path selection
JUNIPER NETWORKS INC0 citations62
US12137045B2Nov 5, 2024
Metric-based multi-hop path selection
JUNIPER NETWORKS INC1 citations62
US12003379B2Jun 4, 2024
Service and topology exchange protocol having client-driven active-active repositories with high availability
JUNIPER NETWORKS INC0 citations58